- Oops!Something went wrong.Please try again later.
The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.
2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks.
The combination was well-tolerated.
"Apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer, and we will not pursue an approval unless we believe our candidate therapy offers a substantial benefit," added Joseph K. Belanoff, MD, Corcept's Chief Executive Officer.
Enrollment for the trial is stopped.
The will initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in Q1 of 2022.
Price Action: CORT shares are down 7.75% at $21.2 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.